## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	rden
houre por roeponeo	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)  1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol					5.	5. Relationship of Reporting Person(s) to Issuer						
RODRIGUEZ RAUL R				RIGEL	PH.	ARMAC	CEU'	TICALS	INC [RIGL]		(Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.  (Street)  SOUTH SAN FRANCISCO, CA 94080 (City) (State) (Zip)			1100	3. Date of Earliest Transaction (Month/Day/Year) 01/24/2018  4. If Amendment, Date Original Filed(Month/Day/Year)  Table I - Non-Derivative Securities Acqu							X Officer (give title below) Other (specify below)  CEO, President  6. Individual or Joint/Group Filing(Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person  uired, Disposed of, or Beneficially Owned				
			(Zip)							s Acquir					
1.Title of Sec (Instr. 3)				Execution Date, if any (Month/Day/Year) Code (Instr. 8) (I		A) or Disposed of (D) (nstr. 3, 4 and 5)  (A) or (A) or (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		C F D o	Ownership orm: Oirect (D) r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Re	eport on a sep	parate fille for each c	lass of securities se	iiciiciuii)		ied directi	,	Person	s who respond						1474 (9-02)
Reminder: Ro	eport on a sep	sarate fille for each C		- Derivat	tive S	Securities	Acqu	Persons in this f a curren	s who respond form are not re ntly valid OMB used of, or Benef nvertible securi	equired to B control ficially O	to respond un I number.				1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction	Table II 3A. Deemed Execution Date, if	- Derivat (e.g., pu 4. Transac Code	tive S	Securities alls, warr	Acquants, r of e	Person: in this f a current tired, Disponentions, co 6. Date Ex Expiration (Month/Da	form are not rently valid OMB  seed of, or Beneficertible securions  ercisable and  Date	equired to B control ficially Ov ties)	to respond un I number. wined and Amount crlying es	nless the fo	orm displays  9. Number of	10. Ownersl Form of Derivati Security Direct (I or Indire	11. Natur of Indirec Beneficia Ownersh : (Instr. 4)
Title of     Derivative     Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	- Derivat (e.g., pu 4. Transac Code	tive S	Securities alls, warra 5. Numbe Derivative Securities Acquired or Dispose (D) (Instr. 3, 4	Acquants, r of e	Personin this fa currentired, Disposoptions, co 6. Date Expiration (Month/Date Expiration Expiratio	orm are not rently valid OMB seed of, or Benefinvertible securi ercisable and Date tay/Year)  Expiration	equired to B control ficially Over ties)  7. Title a of Under Securities	to respond un I number. wined and Amount crlying es	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownersl Form of Derivati Security Direct (I or Indire	11. Natur of Indirec Beneficia Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
RODRIGUEZ RAUL R RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO, President		

# **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	01/26/2018
Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.